Eisai’s epilepsy drug Fycompa to launch in USA

2 January 2014
eisai-logo-big

The US subsidiary of Japanese pharma major Eisai’s (TYO: 4523) that its epilepsy drug Fycompa (perampanel) will be available to eligible patients by prescription in the USA beginning January 6, something of a delay given that the drug was approved by the Food and Drug Administration in October 2012.

Fycompa is an adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy age 12 years and older. The drug is the first non-competitive AMPA glutamate receptor antagonist to be approved by the FDA, the company noted.

Fycompa has been designated by the US Drug Enforcement Administration as a federally controlled substance (CIII). The supply source from Eisai’s UK production facility was cleared by the FDA last fall (The Pharma Letter September 11, 2013). Fycompa has also been approved in the European Union, Canada, Switzerland and Israel.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical